At close: June 28 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
42,063.9270
38,075.3200
28,917.6170
13,393.2030
-20,556.7970
Operating Income
-42,063.9270
-38,075.3200
-28,917.6170
-13,393.2030
20,556.7970
Net Non Operating Interest Income Expense
725.6010
269.6820
-230.5120
-271.3440
-443.0200
Other Income Expense
1,472.6150
-4,388.1480
10,432.9540
-3,479.9840
3.9960
Pretax Income
-39,865.7110
-42,193.7860
-18,715.1750
-17,144.5310
20,117.7730
Tax Provision
--
--
25.6290
--
--
Net Income Common Stockholders
-39,865.7110
-42,193.7860
-18,740.8040
-17,144.5310
20,117.7730
Diluted NI Available to Com Stockholders
-39,865.7110
-42,193.7860
-18,740.8040
-17,144.5310
20,117.7730
Basic EPS
-6.72
-7.64
-4.31
-6.30
4.63
Diluted EPS
-6.72
-7.64
-4.31
-6.30
4.63
Basic Average Shares
6,572.0460
5,521.4870
4,352.4970
2,733.9180
4,347.4770
Diluted Average Shares
6,572.0460
5,521.4870
4,352.4970
2,733.9180
4,347.4770
Total Operating Income as Reported
-42,063.9270
-38,075.3200
-28,917.6170
-13,393.2030
20,556.7970
Total Expenses
42,063.9270
38,075.3200
28,917.6170
13,393.2030
-20,556.7970
Net Income from Continuing & Discontinued Operation
-39,865.7110
-42,193.7860
-18,740.8040
-17,144.5310
20,117.7730
Normalized Income
-40,428.1070
-37,370.5490
-26,956.1720
-13,659.0590
20,117.7730
Interest Income
1,024.8710
584.9660
71.0720
23.1150
26.1310
Interest Expense
299.2700
315.2840
301.5840
294.4590
469.1510
Net Interest Income
725.6010
269.6820
-230.5120
-271.3440
-443.0200
EBIT
-39,566.4410
-41,878.5020
-18,413.5910
-16,850.0720
20,586.9240
EBITDA
-34,759.5820
-38,133.2200
-15,121.7130
-15,196.4750
21,135.1020
Reconciled Depreciation
4,806.8590
3,745.2820
3,291.8780
1,653.5970
548.1780
Net Income from Continuing Operation Net Minority Interest
-39,865.7110
-42,193.7860
-18,740.8040
-17,144.5310
20,117.7730
Total Unusual Items Excluding Goodwill
562.3960
-4,823.2370
10,399.2000
-3,485.4720
--
Total Unusual Items
562.3960
-4,823.2370
10,399.2000
-3,485.4720
--
Normalized EBITDA
-35,321.9780
-33,309.9830
-25,520.9130
-11,711.0030
21,135.1020
Tax Rate for Calcs
--
--
0.0002
--
0.0003
Tax Effect of Unusual Items
--
--
2,183.8320
--
--
12/31/2020 - 2/9/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CYCN Cyclerion Therapeutics, Inc.
2.3000
+5.99%
KA Kineta, Inc.
0.5307
-5.43%
CDT Conduit Pharmaceuticals Inc.
1.0600
+3.92%
PTIX Protagenic Therapeutics, Inc.
0.9050
-3.52%
THAR Tharimmune, Inc.
3.5300
+9.97%
NLSPW NLS Pharmaceutics AG
0.0345
+7.48%
LIXT Lixte Biotechnology Holdings, Inc.
2.3700
-2.47%
LIPO Lipella Pharmaceuticals Inc.
0.4500
-3.43%
NAUT Nautilus Biotechnology, Inc.
2.3400
+2.63%
AKTX Akari Therapeutics, Plc
2.7000
+0.75%